Vendors jockey for bioprocess position

Pall Corp has unveiled the PallSep Biotech system for separating target molecules from process fluids via vibrating membrane filtration technology. Encapsulated hydrophilic polyethersulfone membrane filter modules provide for "gentle" separation, according to an announcement. The system is intended for use in therapeutic-vaccine and antigen-extract processes.

Pall has also recently launched a 5-milliliter phase reaction conversion (PRC) prepacked chromatography column for protein purification processing. The scalable columns support ion exchange and mixed-mode chromatography to aid in processing consistency. They are available in various separation media for such applications as native and recombinant proteins, plasmids, vaccines, monoclonal and polyclonal antibodies, and plasma derivatives.

Separately, Sartorius Stedim Biotech and Corning announced late last month a collaboration that builds on the companies' existing relationship. The pair will co-market cell culture products through a combined product catalogue and work together on marketing and sales.

- see the PallSep system and PRC column announcements
- here's the Sartorius/Corning announcement

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.